Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Want to see BLRX full AI Analyst Report?
Earnings Data
Report Date
Aug 13, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.15Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed meaningful clinical progress—most notably initiation and first dosing in the GLIX1 first-in-human study, supportive preclinical data including activity in temozolomide-resistant models, ASCO exposure, and accelerating APHEXDA sales via partner Ayrmid. Offsetting these positives were materially weaker financial results versus prior year (swing to a $2.6M net loss, a ~93% drop in nonoperating income), higher R&D spend tied to GLIX1, and a modest cash runway into H1 2027. Operational transparency was limited on some site activations, dosing and commercial execution by the partner. Overall, scientific and programmatic momentum is strong but financial and disclosure constraints introduce caution.Company Guidance
GLIX1 First-in-Human Trial Initiation and Dosing
Phase I/IIa trial for GLIX1 in glioblastoma (GBM) initiated; first patient dosed at NYU Langone. Trial Phase I expects up to 30 recurrent GBM/high-grade glioma patients to determine MTD/RDose based on safety, PK/PD and preliminary efficacy. Periodic updates expected in H2 2026, full dose-escalation results anticipated in 2027.
Strong Preclinical Efficacy and Differentiators for GLIX1
New preclinical data: robust, dose-dependent tumor growth inhibition and survival benefit in two orthotopic CDx GBM models; robust antitumor effect in a temozolomide-resistant PDX where temozolomide showed no effect. GLIX1 crosses the blood-brain barrier and restores TET2 activity, supporting monotherapy and combinations (notably with PARP inhibitors) and two abstracts accepted for ASCO online publication.
Commercial Traction for APHEXDA via Partner Ayrmid
Ayrmid reported APHEXDA sales of $2.5M in Q1 2026 vs $1.4M in Q1 2025, an increase of approximately 78.6%, resulting in $0.5M of royalty revenue to BioLineRx.
Revenue Increase Driven by Royalties
BioLineRx revenues rose to $0.5M for Q1 2026 from $0.3M in Q1 2025 (an increase of ~$0.2M, or ~66.7%), reflecting higher royalties from APHEXDA commercialization.
Ongoing Motixafortide Clinical Activity in PDAC
Columbia University–led randomized Phase IIb CheMo4METPANC trial (motixafortide + cemiplimab + gemcitabine/nab-paclitaxel) is enrolling and tracking well; a prespecified interim futility analysis is planned when 40% of PFS events are observed (anticipated later this year).
Strategic Rights and Development Opportunities
BioLineRx retained PDAC rights to motixafortide and benefits from Ayrmid's broader development/commercial rights (excluding solid tumors and non-Asia territories). Ayrmid is also developing motixafortide in sickle cell disease, representing potential future revenue expansion.
Cash Position
Cash and equivalents of $17.4M at quarter end, which the company states is sufficient to fund the operating plan into the first half of 2027.
BLRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BLRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 27, 2026 | $3.16 | $3.37 | +6.65% |
Mar 23, 2026 | $2.65 | $2.32 | -12.45% |
Nov 24, 2025 | $3.25 | $3.50 | +7.69% |
Aug 14, 2025 | $3.94 | $3.77 | -4.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bioline RX Ltd Sponsored ADR (BLRX) report earnings?
Bioline RX Ltd Sponsored ADR (BLRX) is schdueled to report earning on Aug 13, 2026, Before Open (Confirmed).
What is Bioline RX Ltd Sponsored ADR (BLRX) earnings time?
Bioline RX Ltd Sponsored ADR (BLRX) earnings time is at Aug 13, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLRX EPS forecast?
BLRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.15.